These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22374926)

  • 41. Is the device development process adequate.
    Somberg JC
    Am J Ther; 2010; 17(2):123-4. PubMed ID: 20305398
    [No Abstract]   [Full Text] [Related]  

  • 42. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
    Kesselheim AS
    Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Familiar arguments: debate over device user-fee act reflects FDA's record.
    Lee J
    Mod Healthc; 2012 Apr; 42(14):16. PubMed ID: 22533178
    [No Abstract]   [Full Text] [Related]  

  • 44. Defending substantial equivalence: an argument for the continuing validity of the 510(k) premarket notification process.
    Flaherty JM
    Food Drug Law J; 2008; 63(4):901-27. PubMed ID: 19601388
    [No Abstract]   [Full Text] [Related]  

  • 45. Myths and realities in medical packaging.
    Pilchik R
    Med Device Technol; 2003 Mar; 14(2):16-7. PubMed ID: 12698692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Medical devices; 30-day notices and 135-day PMA (premarket approval application) supplement review--FDA. Direct final rule.
    Fed Regist; 1998 Apr; 63(80 Pt 1):20530-3. PubMed ID: 10179319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conducting clinical studies in Italy.
    Donawa M
    Med Device Technol; 2005 Oct; 16(8):21-4. PubMed ID: 16355966
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Strategic planning for U.S. premarket approval submissions.
    Donawa M
    Med Device Technol; 2006 Sep; 17(7):21-3. PubMed ID: 17039953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medical device recall authority--FDA. Final rule.
    Fed Regist; 1996 Nov; 61(225):59004-22. PubMed ID: 10163116
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmaceuticals and Medical Devices: FDA Oversight.
    White RS;
    Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-33. PubMed ID: 29361662
    [No Abstract]   [Full Text] [Related]  

  • 51. Medical devices; exemptions from premarket notification; class II devices; vascular tunnelers. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Mar; 65(43):11466-7. PubMed ID: 11010650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The FDA approval process for medical devices: an inherently flawed system or a valuable pathway for innovation?
    Fargen KM; Frei D; Fiorella D; McDougall CG; Myers PM; Hirsch JA; Mocco J
    J Neurointerv Surg; 2013 Jul; 5(4):269-75. PubMed ID: 22764203
    [No Abstract]   [Full Text] [Related]  

  • 53. A pivotal medical-device case.
    Picca SM
    N Engl J Med; 2008 Apr; 358(16):1758. PubMed ID: 18426011
    [No Abstract]   [Full Text] [Related]  

  • 54. The U.S. medical device industry: entrepreneurs' future hinges on reforms at the Food and Drug Administration.
    Kimbell JJ
    Food Drug Law J; 1996; 51(2):339-43. PubMed ID: 11822328
    [No Abstract]   [Full Text] [Related]  

  • 55. FDA pilot programme in support of global harmonisation.
    Donawa ME
    Med Device Technol; 2003 Nov; 14(9):32-4. PubMed ID: 14682021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Food and Drug Administration's regulation of risk disclosure for implantable cardioverter defibrillators: has technology outpaced the Agency's regulatory framework?
    Basile EM; Lorell BH
    Food Drug Law J; 2006; 61(2):251-72. PubMed ID: 16903031
    [No Abstract]   [Full Text] [Related]  

  • 57. Reflections on the year.
    Neale M
    Med Device Technol; 2001 Dec; 12(10):28-9. PubMed ID: 15966142
    [No Abstract]   [Full Text] [Related]  

  • 58. Left to their own devices: breakdowns in United States medical device premarket review.
    Hines JZ; Lurie P; Yu E; Wolfe S
    PLoS Med; 2010 Jul; 7(7):e1000280. PubMed ID: 20634922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medical device specificities: opportunities for a dedicated product development methodology.
    Santos IC; Gazelle GS; Rocha LA; Tavares JM
    Expert Rev Med Devices; 2012 May; 9(3):299-311. PubMed ID: 22702261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New efforts to harmonise clinical evaluation.
    Donawa M
    Med Device Technol; 2006; 17(9):28, 30, 32. PubMed ID: 17240684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.